hmpl-453 with itraconazole
hmpl-453 with itraconazole: developed by 1 company · 1 clinical trial tracked. Updated within the last hour.
Lead developer: HUTCHMED (China) Limited (HCM)
Development Pipeline (1)
| Company | Phase |
|---|---|
| HUTCHMED (China) Limited (HCM) | Phase 1 |
Clinical Trials (1)
An Open-Label, Two-Part, Two-Period, Fixed Sequence Crossover I Study to Evaluate the Effect of CYP3A and P- Glycoprotein Inhibitor Itraconazole and CYP Enzyme Inducer Rifampicin on the Pharmacokinetics of HMPL-453 Tartrate Tablets in Healthy Subjects
Frequently asked questions
Who is developing hmpl-453 with itraconazole?
hmpl-453 with itraconazole is being developed by HUTCHMED (China) Limited.
How many clinical trials involve hmpl-453 with itraconazole?
BioSniper tracks 1 clinical trial involving hmpl-453 with itraconazole.
Analyze HUTCHMED (China) Limited & hmpl-453 with itraconazole with AI
Full trial data, mechanism of action, competitive landscape, and AI-powered insights.
- 200 free AI credits / month to run live multi-agent analysis
- Watchlist, catalyst alerts & the biotech event calendar
- Full pipeline, financials & FDA data on every company